Plain-English translation of NCT07737054 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing psilocybin—a psychedelic compound—combined with trauma-focused psychotherapy to treat post-traumatic stress disorder (PTSD). The treatment brings together structured preparation sessions, two doses of the medication, and follow-up therapy sessions designed to help your brain process traumatic memories in a new way. Researchers believe this medication may help people change how they relate to their trauma and rebuild their sense of self.
Many people with PTSD don't get enough relief from standard therapies and medications, and their symptoms remain disabling for years. This study explores whether this medication, given in a controlled therapeutic setting, might help people process trauma more quickly and effectively by increasing emotional openness and flexibility.
You likely qualify if…
You likely don't qualify if…
You will attend preparatory sessions where therapists help you prepare mentally and emotionally for the treatment. Then you'll receive two doses of the medication—first 15 mg, then 25 mg—in controlled clinical sessions where therapists support you throughout the experience. Between and after these dosing sessions, you'll have integration therapy appointments to help you process and make sense of what you experience. The entire program is designed to be structured, supported, and safe.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
Israel